pharma competitive intelligence Archives - Business Intelligence

Tag: pharma competitive intelligence

Pharma secondary packaging market

Infiniti’s Competitive Intelligence Solution for A Prominent Company in The Pharma Secondary Packaging Market: Exploring Key Packaging Innovations And competitive landscape Insights

In pharmaceuticals, secondary packaging constitutes the packaging which does not come in direct contact with the dosage form. Pharma secondary packaging is becoming widely adopted and essential as they offer critical functionalities, such as, for physical and barrier protection, secondary containment, adherence to regulations, and consumer safety. It also creates a buffer and protects primary packages from each other during transportation.

Business challenge

A prominent pharmaceutical company headquartered in San Francisco, CA sought to explore the changing trends in the secondary pharma packaging market by focusing the research on major design/technology innovations and best practices adopted by leading players in the pharma secondary packaging market. Through the engagement, the client wanted to support their future packaging developments and track industry trends over time. By leveraging Infiniti’s competitive intelligence solution, the pharmaceutical company wanted to understand the competitor landscape in the US and European pharma secondary packaging market, new features of secondary packaging being incorporated by competitors, product portfolio descriptions, and competitor strategies to promote adherence.   

Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma secondary packaging market? Request a complimentary proposal.

Our Approach

Experts at Infiniti Research started by delving deeply into the pharma secondary packaging market transformation over the past decade in the US and Europe. This involved a well-balanced combination of primary and secondary research. Telephonic discussions were undertaken with over 45 respondents with expertise in the development, sales, marketing, and usage of products and services related to secondary packaging market such as pharmaceutical packaging specialists, packaging engineers, and packaging development experts. The secondary research undertaken by our analysts included comprehensive research materials from company websites, industry news CPA, HCPC, CHPA, packaging digest, and public database.

Through extensive competitive intelligence study and research methodologies, experts at Infiniti Research were able to identify the top pharma secondary packaging designs that are predominantly used. This includes medication adherence packaging, extended labels, and increasing use of sustainable materials in pharma secondary packaging. Furthermore, Infiniti’s competitor landscape assessment also identified some of the key competitors in the US and Europe, their respective packaging initiatives, and critical initiative undertaken to promote adherence.

With a focus to ensure product integrity, better manufacturing efficiency, and enhancing customer satisfaction, experts at Infiniti Research have identified that companies are developing innovative technologies such as thermochromic indicators and contemporary cartons designs. Furthermore, with Infiniti’s recommendation, the client adopted robotics and process automation that significantly improves production output, lowers operating cost, and enhances worker safety.

Business Impact

By leveraging Infiniti’s competitive intelligence solution, the client was able to successfully track their key market competitors and identify some of the most innovative and viable trends in the pharma secondary packaging market. Apart from this client was also able to:

  • Increase investments on their primary and secondary packaging lines by adopting technologies which result in faster turn-around time, fewer errors, and higher adaptability to incorporate and reproduce design changes
  • Collaborate with the CPO to formulate innovative packaging designs which are senior-friendly, child- resistant, medication adherence promoting, and offers unique dispensing mechanisms
  • Expedite early market entry for biologics and personalized medicine by identifying advancements such as 3D printing in pharmaceutical packaging
  • Reduce operational cost by 30% within this first quarter by adopting RPA into packaging operations
  • Focus on packaging designs that are cost-effective and have shorter production turnaround times
  • Incorporate adherence features in the secondary packaging design to help practitioners promote the use of the drugs to the patients
  • Build an effective planning and production process to minimize packaging errors and prevent product recalls, saving the company over $1.2 million within six months

For similar engagements for your business, get in touch with an industry expert

pharma M&A

Capturing Value from Pharma M&A: Critical Considerations for Success

The pharmaceutical industry is one of the major sectors that is actively involved in huge mergers and acquisition (M&A) deals, both in terms of numbers of deals and the amount of money spent. Most companies in the sector, especially the big pharma consider pharma M&A as a major factor to bolster innovation and overall growth. A recent research by our pharma industry experts shows that revenues coming from innovations sourced outside of Big Pharma is currently stands at over 45%. Over the years, several large, game-changing deals have continuously and profoundly changed the competitive landscape of the sector, while smaller yet significant transactions remain an integral part of pharma industry operations.

Why Pharma M&A is a driver of strategic repositioning?

Pharma M&A has become a common practice for companies that have non-diverse pipelines or have top revenue drugs that are nearing patent expiration and subsequent generic erosion. According to industry experts at Infiniti Research, some of key reasons why companies favor pharma M&A include:

  • The critical size requirements across various market segments have increased exponentially over the years. At this rate, it becomes nearly impossible for a single company for companies to survive on their own. This made strategic pharma M&A a necessity for most companies
  • Large mergers in the pharma industry allow bundling of sub-critical businesses, and thereby change the culture and to build new platforms
  • Another motivation for pharma M&A is to capture annual cost synergies by scaling up

For more insights on our portfolio of services for companies in the pharma industry

Consideration for successful M&A

Achieving Successful Integration Post Pharma M&A

Approximately only 60% of pharma merger deals succeed in the long run. A successful merger is one wherein the resulting company achieves the strategic intentions driving the merger when the deal was initially formed. Mergers that fail often show traits including focusing more attention on back-office integration, cost control, and systems consolidation.

Creating business synergies

Revenue increases during pharma M&A can often more difficult to achieve and take longer than expected. During pharma mergers and acquisitions teams must develop strategies such as the degree to which the existing portfolios need to be rationalized, how teams can be used to increase efficiency, how salesforce can be consolidated to remove overlap, and how the projects of each of the brands can be enhanced.

Defining the integration strategy

The successful integration of two companies largely depends on having a consistent approach with strategic intent. Guiding principles, priorities, and governance must reflect the logic behind the merger. A reliable integration strategy must be efficient in articulating both financial and nonfinancial goals, as well as risk-mitigation strategies.

Request a free proposal for more insights on how we can support your pharma M&A efforts.

Pharma manufacturing

Finding the Future of Pharma Manufacturing – Strategies to Reduce Costs and Boost Efficiency

The growing rate of the aging population with significant unmet needs is creating a high demand for pharma manufacturing companies. However, pharma manufacturing companies are also facing headwinds from unattractive pricing and volume expansion across all regions, growing size and bargaining power of payers, the emerging biological patent cliff, and the growing competitive pressure. Amidst these challenges pharmaceutical manufacturers are seeking to reduce operational costs and streamline cycle time within R&D. Below, our pharma industry experts have listed out some key strategies that pharma manufacturing companies can use to gain efficiency and enhance their R&D process.

Heads of R&D at major pharmaceutical companies agree that there is a critical need to substantially increase the number of innovative new medicines, while eliminating inefficiencies that drive up R&D costs. Request a free proposal to know how we help pharma manufacturers achieve this.

Partial outsourcing

Outsourcing at least a small part of research and development processes to emerging markets and low-cost centers can help pharma manufacturers to considerably reduce their overall costs. Companies in the pharma sector can take inspiration from other significant industries to relocate certain operations to areas where labor costs are cheaper. However, some pharma manufacturing companies are often skeptical about outsourcing R&D as it carries a heavy risk. This is one of the prime reasons why experts suggest shifting only non-core activities to low-cost centers.

Business process management

Companies in pharma manufacturing can gain increased efficiency by relying on business process management. Redundancies in processes can be reduced through automation and optimization. This can also help pharma manufacturers reduce their time to market and enable regulatory compliance with R&D phase of a new drug such as simplifying clinical trial processes, minimizing errors, and creating a collaborative research environment.

Looking for solutions to address your key business challenge? Get in touch with an expert for unparalleled business insights.

Eliminate ‘non-value adding’ activities

This is also often termed as lean process improvement. This method has proven effective for increasing efficiency and reducing operating costs for companies across various industries. Lean techniques can help pharma manufacturing companies to improve workplace efficiency within laboratories, while the focus on eliminating unnecessary steps can help speed up certain processes to reduce cycle time.

Strategic partnerships

This is not a strictly process improvement technique, but an external strategic alliance can help pharmaceuticals manufacturing companies to streamline and improve operations that one company operating in isolation may not succeed in doing.

Gain more insights on Infiniti’s solutions for the pharma industry

pharmaceutical industry

Illuminating the impact of Brexit on Europe’s Pharmaceutical industry

Pharmaceutical industry products are in the list of top five products that are most imported and exported from the UK to the EU and vice versa.

Brexit can have several implications of Europe’s pharmaceutical industry. From product development to market approval to the shipping of medicines and medical devices, pharmaceutical companies can expect to be affected in a broad range of areas. Companies in the pharmaceutical industry in the UK will have to manage the impact of Brexit carefully to prevent some of the negative aspects. However, uncertainty will have adverse effects on pharmaceutical and life sciences companies in other European countries as well. Experts at Infiniti predict how Brexit will affect life science and pharmaceutical industry.

Rising demand for personalized treatments, an ageing population, and the rise of new manufacturing technologies are some of the primary growth opportunities for the UK pharmaceutical sector. Request a free proposal to know how our solutions can help you stay prepared to cope with the market trends and changes.

Relocating European Medicines Agency (EMA)

One of the key pharmaceutical industry market access challenges that Brexit brings along with it, irrespective of the path it takes is related to the future location of the European medicines agency. Since its inception in 1995, EMA had been located in London. However, the Netherlands has now won the bid to host new EMA headquarters post-Brexit. With the EMA headquarters soon moving to Amsterdam, they may implement several changes to rules for medicinal products that are developed and tested in the UK. However, the extent of Brexit-induced changes to the pharmaceutical industry has yet to be decided.

Movement of people and pharma products

Pharma products form a considerable part of goods that are exported to and from the UK. Any post-Brexit hurdles to the free movement of goods could mean trouble for those supplies, potentially leading to temporary drug shortages. This is especially true in the case of drugs such as medicinal insulin that are not manufactured in the UK nor is it easily stored, as it requires temperature-controlled conditions. In order to reduce the risk of drug shortages in the case of a no-deal Brexit, the British government has asked pharmaceutical companies to add a minimum of six weeks’ worth of additional backup supply of medicines to their usual buffer stocks by the exit date, and to ensure that contingency plans were in place for drugs with shorter shelf lives. However, it is not only the movement of medicines that’s at risk. As the possibility of stricter rules regarding the flow of people between the UK and the EU looms, companies in the pharmaceutical industry are concerned about their ability to attract talent from outside Britain in the future. It is vital that pharmaceutical companies to still be able to access the best talent from around the world.

Emerging markets represent an exceptional opportunity for the pharmaceutical sector. Get in touch with our experts for more insights on how to capture the true value of the pharmaceutical market.

Change in the UK’s contribution to drug regulation

UK plays a major role in drug regulation in the EU through the work of the Medicines and Healthcare Products Regulatory Agency (MHRA). The UK frequently serves as rapporteur/co-rapporteur in the EU’s centralized procedure and as the reference member state in the decentralized procedure. It will prove to be a challenging task to replace the MHRA’s capacity and expertise, particularly if the timetable for reform is aggressive.

 

Safe supply of blood and organs

Another pressing challenge faced by companies in the pharmaceutical industry due to Brexit is linked to ensuring blood and blood products are safe. If there is a no-deal Brexit, the EU Blood Directives will not apply to the UK and it will be considered a third country by the EU regarding sharing blood, blood components, and information. The UK Government has declared that in the event of a no-deal, the current blood safety and quality standards for blood and blood components will remain the same, and therefore adhere to EU standards, allowing them to be imported into the EU. Similarly, the UK Government has laid out its provisions for ensuring the supply, as well as the safety and quality, of organs, tissues, and cells in the event of a no-deal. The UK would no longer be part of the EU Organ and EU Tissues and Cells directives, however, relevant UK establishments, such as stem cell laboratories and fertility clinics, would be required to work to the same standards. These organizations would need to individually agree on import and export of the products with EU and EEA authorities and establishments.

Learn more about Infiniti’s solutions for the pharmaceutical industry.

Recent Posts

Trends in pharmaceutical industry

Pharmaceutical Industry Challenges to Watch Out for in 2019

Despite several major challenges in the way over the past couple of years, the pharmaceutical industry continues to thrive. However, the sector is not completely free from challenges this year either. Due to the nature of the industry, cost aspects and stricter regulations remain as constant pharmaceutical industry challenges. Furthermore, pharma companies are also under scrutiny by health insurers, consumers, and the government for greater transparency and accountability. In this blog, industry thought leaders from Infiniti Research gives an overview of the current scenario in the pharma industry and also discusses the key pharmaceutical industry challenges that companies can expect this year.

Pharmaceutical industry challenges 2019

Pharmaceutical industry challenges 2019Patent cliffs

The expiry of a drug patent and the consequent drop in the sales of the product which previously held a large market share is known as a patent cliff. These patent cliffs give competitors the opportunity to produce and patent a comparable brand name drug. In the next couple of years, this is going to be one of the key pharmaceutical industry challenges affecting prescription drug sales worldwide.

As the pharma industry becomes increasingly globalized, complex, and highly regulated, the sector must become more streamlined and cost-efficient at manufacturing and distributing its products. Request a free proposal to know how our solutions can help you streamline your operations and overcome critical pharmaceutical industry challenges.

Foreign counterfeit drugs

The increasing flow of foreign counterfeit drugs into the American market is another key challenge that would affect pharma companies in a big way. As several pharmaceutical manufacturers are moving abroad to attain lower costs, it must be ensured that they meet the U.S. quality standards while adhering to the local regulations overseas. It is also essential to block all illegal trafficking of counterfeit medications. In order to achieve this, stringent regulations and standards must be imposed on all vendors and third parties involved in the manufacturing and transportation of pharma products. For pharma companies operating out of or distributing drugs in the UK, Brexit will make it even more difficult.

US drug prices

The issue of rising drug costs in the US continues to persist. The price freezes in 2018 was a result of constant pressure from patients, politicians, and other regulatory bodies. As a result, a proposal was made to introduce an international pricing index through Medicare with the aim of reducing Medicare spending considerably. This proposal was widely criticized due to concerns and to add on to the pharmaceutical industry challenges several companies hiked their prices even further in the early 2019. One of the key pharmaceutical industry challenges in the US right now is to control drug prices and provide more accessible and affordable healthcare to the Americans.

Have unanswered questions about the current pharmaceutical industry challenges and how our solutions can help you formulate effective strategies to overcome them? Get in touch with our experts for queries relating to our services for pharma companies.

Shift to patient-centric healthcare

The advent of technology has made the patients more informed and they are now likely to play a more active role in any treatment plan prescribed by their doctor. While patient-centric healthcare provides several opportunities, it can also add on to the current pharmaceutical industry challenges. The primary challenge will be to determine how to leverage the power of health technology and focus on partnerships directly with the customers rather than with the medical community. In order to survive despite the rising prices, companies in the pharma industry must foster better relationships and build trust with the consumers. Also, the rising consumerism has prompted customers to look at prescriptions from a more value-benefit perspective. As healthcare consumerism rises, pharma companies must find ways to provide real-world research backup claims to justify their products and prices.

Learn more about our market intelligence solutions

Business Forecasting

Steps in Competitor Analysis of Pharma Companies

It is no new knowledge that the present scenario in the pharmaceutical industry is highly competitive.In the recent years, the pharma market has become even more competitive due to the availability of branded and generic product segments. Despite evidence to the contrary, several pharmaceutical companies perceive their competitive world as a relatively flat landscape. Consequently, numerous pharma companies and professionals still resort to outdated and superficial competitor analysis that limit their perceptions to competitors’ product and corporate profiles, particularly promotional spending and sales force allocations. These simplistic, often short-sighted approaches place pharma companies at risk from competitive threats and dangerous blind spots. As the pharmaceutical industry transitions to a shorter and less profitable life cycle model, competitive planning for brands and companies have become critical for growth. The foundation of this planning is competitor analysis, which is essentially the process of assessing and understanding the competitors to help design winning strategies and tactics. The drug development process is not only a process to formulate the most successful product or treatment for a particular condition, but also to research the market and successfully identify the competitors. Other key benefits of undertaking competitor analysis include targeting the right customers, market potential forecasting, and matching the competitor pricing. Here are some of the steps involved in conducting competitor analysis:Request Free Proposal

Finding the right team

The first step involved in conducting a  systematic, insightful and multidimensional competitor analysis is to find the right team. For any analysis, it’s imperative to have the ideal frameworks, processes, and tools. This could include a multidisciplinary team of internal consultants and external professionals if required. Firms should not solely depend on competitive intelligence dealers, who mainly focus on accumulation of data and competitive surveillance. Instead, they should use people with expertise in elaborate competitive analysis, planning, strategy, and implementation. With the help of these professionals. Companies can gain access to proper methodologies, tools, and structures to lead and assist the development of a competitive analysis process.

Competitive Personality Analysis

Many pharma companies make the mistake of assuming that their company is not a part of the competitive mix. However, corporate self-analysis is an indispensable part of the competitor analysis. Every company has its own distinct personality, and competitive personality analysis involves unearthing the personality of a company. It addresses critical questions like how a company thinks and acts, what is the competitor’s product profile, what salesforce will be used to back the competitor’s product, what will be the competitive differentiation, etc. Based on corporate presentations, executive profiles, competitive intelligence, and other information gathered by addressing such questions, pharma companies can penetrate into a competitor’ head and decipher their way of thinking and also their future course of action. 

Strategic stakeholder analysis

In today’s market, when physicians prescribe a particular drug and patients want that drug, sometimes they end up buying a different brand. Prescription power is now being transferred from patients and physical care providers to other strategic stakeholders. These stakeholders include regulators, governments, professional societies, policymakers, the media, health technology evaluation groups, retailers, etc. As stakeholders play an essential role in the adoption and use of particular brands, a detailed analysis of strategic stakeholders should be a critical aspect of every competitor analysis.

SWOT analysis

A SWOT analysis helps to identify and evaluate the strengths, weaknesses, opportunities, and threats that a company faces. The information gained is used to analyze the position of a company as well as that of their competitors. A SWOT analysis informs the upper management what the industry is outshining in, the improvements required, exploiting growth opportunities if possible and the preemptive measures that need to be taken to safeguard a company or shareholder value.


To know more about competitor analysis for pharma companies

Ask an analyst


Related Posts

Pharmaceutical Industry

Pharmaceutical Industry Challenges – Roadblocks to the Industry’s Growth Prospects

The growth of the pharmaceutical industry has slowed down over the last few years. Experts suggest that the market has reached its saturation level. However, due to recent advances in technological innovation, the market is anticipated to witness further growth. Innovations such as wearable devices, real-world evidence, telemedicine, nanotechnology, and precision medicine are expected to change the landscape of the pharmaceutical industry. Despite such innovations, the pharma industry has started facing some tough tests recently.

Copy of Copy of banner IR (1)

Pharmaceutical Industry Challenges

Pharmaceutical Industry Growth Slowdown

Numerous market research reports have highlighted the fact that the pharmaceutical industry will experience a slowdown in the next few years since the major markets are nearing their saturation point. Historically, the pharma industry has experienced a sporadic increase in growth rates with the introduction of generic medicines for diseases like hepatitis and cancer. Therefore, it can be estimated that the growth prospects of the pharmaceutical industry are currently dependent on the invention of effective medications.

Biosimilar Showdown

Biosimilar drugs are capable of increasing the efficacy of medicines and patient safety at an economical cost. However, big players in the pharmaceutical industry are opposed to biosimilars as it’s hurting their innovative capacities. In the US, the FDA has approved 41 new medicines, the most in 18 years, with more drugs in the pipeline. The recent Sandoz vs. Agmen case has also brought into limelight the fact that the cheaper version of complex and pricier drugs, called biosimilars, get to patients faster.

With over 15 years of experience in serving customer across the globe, we can help you to gather detailed insights into the market. Contact us today!

Contact USShift to Value-based Payments

As a whole, the healthcare industry is moving towards value-based payments from volume-based or fee-for-service based payments. This system rewards the increment in quality and value of healthcare services. Companies in the pharmaceutical industry are also looking to implement value based purchasing but will face challenges in estimating an appropriate time-frame for manufacturers to demonstrate drug efficacy. Therefore, it will be difficult for new drugs to compete in the value-based payment system.

To gather more insights into our services and their benefits for your business, Request for more info!Get More Info

Business Forecasting

Top 3 Strategies Pharma Companies Must Employ to Mitigate Risks in Emerging Economies

The rapid economic growth in the emerging economies did give a lot of hope to the western pharma and health sciences companies for growth and expansion. But in the recent years, as the fizz around the emerging economies being the land of opportunities has waned out, major names in the pharma industry are having a tough time finding a hold in these unsteady markets. Competition from regional players, fall in commodity prices, complying with the regional laws, and importantly, hiring the right talent, and building a productive workforce, have emerged as major bottlenecks for a majority of the pharma companies.

How do you bell the cat?

Industry experts at Infiniti Research believe that the emerging markets will witness a positive turn in the upcoming years. In fact, there are huge prospects for the pharma revenues to almost double in the next ten years. Therefore, even if the mature markets in the Americas and Europe seem to be a better option now, pharma majors should concentrate on building a full-fledged business strategy for the emerging economies.

The three major ways in which pharma companies can make a lasting impact in the emerging markets are:

1.     Going beyond the commercial model

The basic commercial model is largely hinged on sales and marketing strategies. Perhaps this is where most pharma majors are going wrong. One major error, which many pharma companies commit is not going beyond this model. To make an impact in the emerging economies, one must adapt to the local conditions and come up with solutions which meet the local demands and constraints. Building a supply chain which is attuned to the local licensing nuances is sure to provide a competitive edge to the manufacturers. This is especially true in the case of pharma markets in Africa and the Middle- East.

2.     Expansion of Patient Access

Most emerging economies are constantly struggling with undertreated and underdiagnosed diseases. This situation provides a great platform for the pharma companies to launch their drugs as well as expand their patient access. At the same time care needs to be taken that the drugs manufactured are easily available to lower-income patients in these regions. Pharma heads should work towards striking a fine balance between pricing strategy and market access. Usually opting for voluntary licensing deals play a critical role drawing incremental revenues, broadening patient access, and most of all building goodwill.

3.     Not letting go of innovation

For some reason, pharma majors do not think of emerging economies as suitable hubs for innovative programs. However, there is a lot of scope and need for innovation in this geographical area as well. With a huge number of undertreated diseases, countries in Africa and Asia can, in fact, be converted into a test bed for innovative technologies and drug solutions. Right from digital health, to providing local solutions to health problems – the emerging markets provide a huge scope for experimentation to the pharma manufacturers. The winner in the long-run is going to be the company which leverages these advantages to disrupt the existing market.

Drug Development Pipeline and Key Strategy Analysis for European Pharmaceutical Major

Business Challenge
A leading Europe-based healthcare company wanted to understand its competitor’s strategy, pipeline, and plans for the development and launch of new products.
Situation
The client wanted to conduct a comprehensive assessment of the competitor’s current and future R&D strategies, product and pricing strategies, therapeutic pipeline, and spend on marketing-related activities.
Approach
We conducted secondary research followed by interviews and discussions with market stakeholders to facilitate a detailed analysis of the competitor and to obtain insights into their drug development, marketing, and budgeting activities.
Impact
Based on our insights, the client was able to understand and benchmark against the drug development strategies of its competitor, identify the areas where it was lagging in terms of research and investment, and develop action plans.

Spend and Cost Benefit Analysis for a Branded Generic Drugs Manufacturer

Business Challenge
A leading healthcare service provider wanted to identify its indirect spend on manufacturing activities across various locations in the EMEA region.
Situation
The client wanted to conduct a comprehensive spend assessment to leverage its combined purchasing power across categories and drive cost savings, while realigning the supply chain organization structure for indirect categories.
Approach
We obtained procurement and spend data for the previous four quarters from the client’s accounts payable system. Spend analysis, cost optimization assessment, and procurement process analysis were carried out across the company’s multiple divisions/plants.
Impact
Through cost optimization framework, the client was able to select best possible options for supplier selection and effective spend mix. We also developed a centralized sourcing platform which helped the client in process improvement and save costs on indirect categories.
Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice